Genmab Partners Raised $503M U.S. IPO on Cancer Antibodies with BliNK Biomedical

Genmab Partners Raised $503M U.S. IPO on Cancer Antibodies with BliNK Biomedical

Genmab through collaboration with Blink biomedicals raised a whopping $503 Million through an American initial public offering (IPO) all this got revealed on Friday during an event. Genmab also launched an up to $200 million-per-product cancer therapy with Blink biomedicals. Blink biomedicals got a license approved by Genmab exclusively for antibodies targeting CD47, which Genmab plans to combine with its duo body platform technology to produce new bispecific antibodies for fighting cancer. Genmab CEO Jan van de Winkel, Ph.D. gave his words about this CD47 stating that “CD47 has shown…

Read More

The Bispecific and Complex mAbs Driving Process Development Innovation, Roche

The Bispecific and Complex mAbs Driving Process Development Innovation, Roche

According to a statement by the VP of Roche technical development bioprocessing, Wolfgang Kuhne said that the older processes used to produce monoclonal antibodies like Herceptin and Avastin are not sufficient to produce complex and advanced pharmaceuticals. A bioprocess international European summit was held in Vienna, Austria during which delegates were told that making candidates like ACE910 – a bispecific antibody granted breakthrough designation for Haemophilia last September – had required a considerable process development effort. In his statement, he clarified by saying “There are no more classical standard approaches…

Read More